Drug
Biospecimen Collection
Biospecimen Collection: highest development phase Phase 2, developed by AbbVie, Arcus Biosciences, Geron Corporation and others. 5 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- AbbVie, Arcus Biosciences, Geron Corporation
Trials
| Drug | Phase | Indication |
|---|---|---|
| Biospecimen Collection NCT05756569 | Phase 2 | Bladder Squamous Cell Carcinoma |
| Biospecimen Collection NCT05890352 | Phase 2 | Grade 3b Follicular Lymphoma |
| Biospecimen Collection NCT06536049 | Phase 1/2 | Recurrent Diffuse Large B-Cell Lymphoma |
| Biospecimen Collection NCT05688215 | Phase 1/2 | Borderline Resectable Pancreatic Adenocarcinoma |
| Biospecimen Collection NCT06247787 | Phase 1 | Recurrent Childhood Acute Myeloid Leukemia |
Latest
No recent events.
Follow Biospecimen Collection on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.